Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas

NCT04388852 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04388852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04388852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) Carcinomas
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 20, 2020
Completion date
December 31, 2026
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive variant prostate carcinoma, castration-resistant prostate carcinoma, metastatic clear cell renal cell carcinoma, metastatic malignant solid neoplasm, metastatic prostate carcinoma, metastatic urothelial carcinoma, stage iv prostate cancer ajcc v8, stage iv renal cell cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8